文献速递前列腺癌

无创尿液检测预测前列腺癌主动监测中的分级分组升级:多中心验证及与MRI的比较

Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison with MRI.
PubMed 文献 · J Urol · 2026-04-28

本研究开发并外部验证了一种非指检尿液检测(MyProstateScore 2.0-主动监测,MPS2-AS),用于预测主动监测患者活检时是否升级至GG≥3或GG≥2,并在11家机构进行验证。结果显示MPS2-AS对GG≥3和GG≥2升级的AUC分别为0.82和0.74,均优于mpMRI(0.73和0.64),可避免64%不必要的活检,仅漏检3.2%的GG≥3升级和4.9%的GG≥2升级。

要点

  • MPS2-AS尿液检测对GG≥3升级的AUC为0.82,优于mpMRI的0.73。
  • MPS2-AS可避免64%不必要活检,仅漏检3.2%的GG≥3升级。
  • 以PI-RADS≥3为活检指征会漏检18%的GG≥3升级和35%的GG≥2升级。

核心结论

  • 在多中心主动监测人群中,尿液MPS2-AS对GG≥3和GG≥2升级的预测高度准确且具有临床可操作性,直接比较中显著优于mpMRI。

研究设计与样本

  • 研究衍生并外部验证了MPS2-AS模型,用于预测升级至GG≥3和GG≥2,在11家机构的前瞻性收集尿液标本中进行验证。
  • 验证队列纳入330例计划进行主动监测活检的GG1癌症患者,所有患者接受≥12针系统活检加PI-RADS≥3病灶的靶向活检。

主要发现

  • 活检时31例(9.4%)升级至GG≥3,123例(37%)升级至GG≥2。
  • MPS2-AS预测GG≥3升级的AUC为0.82,mpMRI为0.73;预测GG≥2升级的AUC为0.74,mpMRI为0.64。
  • 活检前MPS2-AS可避免64%的不必要活检,仅漏检3.2%的GG≥3升级和4.9%的GG≥2升级。
  • 以PI-RADS≥3为活检指征会漏检18%的GG≥3升级和35%的GG≥2升级,仅避免50%的不必要活检。
  • MPS2-AS在临床相关亚组(确认性活检与监测活检、黑人与非黑人患者)中表现一致。

关键数值与推荐

  • 验证队列中280例(85%)有活检前mpMRI,其中130例(46%)为PI-RADS 1-2,42例(15%)为PI-RADS 3,108例(39%)为PI-RADS 4-5。

临床怎么用

  • MPS2-AS尿液检测可用于主动监测患者决定是否需要活检,减少计划性活检和系列mpMRI的需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We developed and externally validated a nondigital rectal examination urine test to inform whether biopsy is necessary in patients undergoing active surveillance (AS). Performance and clinical consequences of testing were directly compared with multiparametric MRI (mpMRI). MATERIALS AND METHODS: Biomarker models (MyProstateScore 2.0-Active Surveillance [MPS2-AS]) were derived to predict upgrading to Grade Group (GG) ≥ 3 and GG ≥ 2 and externally validated across 11 practices. Urine was prospectively collected, and patients underwent ≥ 12-core systematic biopsy plus targeted biopsy of Prostate Imaging Reporting and Data System (PI-RADS) ≥ 3 lesions. Diagnostic performance and clinical consequences of urinary testing to determine the need for biopsy were compared with mpMRI. RESULTS: The validation cohort included 330 patients with GG1 cancer scheduled for AS biopsy. Overall, 280 (85%) patients had prebiopsy mpMRI, of which 130 (46%) were PI-RADS 1 to 2, 42 (15%) were PI-RADS 3, and 108 (39%) were PI-RADS 4 to 5. On biopsy, 31 (9.4%) patients upgraded to GG ≥ 3 and 123 (37%) to GG ≥ 2. MPS2-AS provided higher area under the receiver operating characteristic curve than mpMRI for upgrading to both GG ≥ 3 (0.82 vs 0.73) and GG ≥ 2 (0.74 vs 0.64). Clinically, prebiopsy MPS2-AS would have avoided 64% of unnecessary biopsies while failing to detect only 3.2% of GG ≥ 3 upgrades and 4.9% of GG ≥ 2 upgrades. By contrast, the use of PI-RADS ≥ 3 would have failed to detect 18% of GG ≥ 3 upgrades, 35% of GG ≥ 2 upgrades, and avoided fewer unnecessary biopsies (50%). Performance of MPS2-AS was consistent across clinically pertinent subgroups (confirmatory and surveillance biopsy, Black and non-Black patients). CONCLUSIONS: In a multisite AS population, urinary MPS2-AS provided highly accurate and actionable testing for GG ≥ 3 and GG ≥ 2 upgrading, meaningfully outperforming mpMRI on direct comparison. These findings suggest that noninvasive monitoring with MPS2-AS could reduce the need for scheduled biopsies and serial mpMRI.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Tosoian JJ, Meyers JI, Moore B, et al. Noninvasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison with MRI. J Urol. 2026. PMID: 42048777. doi:10.1097/JU.0000000000005095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。